Elanco Animal Health Inc(ELAN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,353 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ELAN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Elanco Animal Health Inc (ELAN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ELAN at 52.2/100 on a 32-signal composite quality model, placing it at rank #1,353 of 2,879 stocks — the top half of the AI-ranked universe. ELAN scores in the top quartile across revenue scale (78.0). Areas of concern include earnings quality (30.0) and institutional flow (35.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 48.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Elanco Animal Health Inc reports quarterly revenue of $1.4B, net income of $57.0M, free cash flow of $-38.0M. Top institutional holders of ELAN by reported 13-F value include DODGE & COX, FMR, BlackRock,, based on the most recent SEC filings. ELAN trades on the NYSE exchange and files with the SEC under CIK 1739104. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELAN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elanco Animal Health Inc directly from SEC EDGAR. Elanco Animal Health Inc's 13F Pro composite quality score has ranged between 8 and 62 since 2021, currently 52.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$1.4B
Net Income
Q1 2026
$57.0M
Free Cash Flow
Q1 2026
$-38.0M
ROIC
Q1 2026
0.9%
D/E Ratio
Q1 2026
0.61
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+6.2% YoYNet Income
-168.6% YoYEPS (Diluted)
-169.1% YoYTotal Assets
+5.9% YoYTotal Debt
-8.9% YoYOp. Cash Flow
+3.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.71B +6.2% | $4.44B +0.5% | $4.42B +0.1% | $4.41B -7.4% | $4.76B +45.6% | $3.27B |
| Net Income | $-232.0M -168.6% | $338.0M +127.5% | $-1.23B -1478.2% | $-78.0M +83.9% | $-483.0M +15.9% | $-574.0M |
| EPS (Diluted) | $-0.47 -169.1% | $0.68 +127.2% | $-2.50 -1462.5% | $-0.16 +83.8% | $-0.99 +23.8% | $-1.30 |
| Total Assets | $13.36B +5.9% | $12.61B -12.2% | $14.36B -7.3% | $15.49B -6.0% | $16.48B -6.9% | $17.69B |
| Total Debt | $4.02B -8.9% | $4.41B -24.1% | $5.81B -6.6% | $6.22B -5.9% | $6.61B -1.0% | $6.68B |
| Operating Cash Flow | $560.0M +3.5% | $541.0M +99.6% | $271.0M -40.0% | $452.0M -6.4% | $483.0M +1278.0% | $-41.0M |
AI Insight: ELAN Financial Trends
Elanco's Q1 2026 revenue hit $1,371M — a record in this dataset — while debt continued its steady decline toward $3,991M, but net income and operating cash flow remain erratic.
• Revenue grew year-over-year from $1,193M in Q1 2025 to $1,371M in Q1 2026, the highest quarterly figure in the dataset.
• Total debt fell from $5,676M in Q2 2024 to $3,991M in Q1 2026, a reduction of roughly $1,685M over seven quarters.
• Net income has been consistently volatile, swinging from $-276M in Q4 2025 to $57M in Q1 2026, with no sustained positive trend.
• Operating cash flow dropped sharply to $13M in Q1 2026 from $237M in Q2 2025, continuing a pattern of large quarter-to-quarter swings.
⚠ Q4 2025 net loss of $-276M is the worst quarter in the dataset — monitor whether Q1 2026's $57M recovery signals stabilization.
⚠ Operating cash flow of just $13M in Q1 2026 despite record revenue raises questions about working capital management and cash conversion.
⚠ Equity has held relatively stable between $6,096M and $6,775M since Q4 2024, suggesting book value is not yet deteriorating materially.
AI Insight: ELAN Ratio Trends
Elanco's profitability remains deeply erratic — Q4 2025's -22.6% operating margin drags the TTM negative despite a Q1 2026 recovery to 6.3%.
• Operating margin swung from -22.6% in Q4 2025 to 6.3% in Q1 2026, but TTM sits at -4.0%, reflecting persistent instability.
• D/E ratio declined from 0.96 in Q2 2024 to 0.61 in Q1 2026, signaling meaningful deleveraging over five quarters.
• ROIC recovered to 3.3% in Q1 2026 after hitting -9.8% in Q4 2025, but TTM ROIC remains negative at -1.9%.
• Q3 2024's 54.3% operating margin and 20.5% ROIC appear to be a one-off event, not a sustainable inflection.
⚠ Q4 2025 operating margin collapsed to -22.6% — monitor whether this reflects a recurring seasonal drag or structural deterioration.
⚠ TTM NPM of -5.0% lags Q1 2026's 4.2% — sustained quarterly profitability needed before TTM turns positive.
⚠ D/E at 0.61 is improving; further reduction could meaningfully lower interest burden and support margin recovery.
Get alerted when ELAN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Elanco Animal Health Inc including:
Top Institutional Holders of ELAN
DODGE & COX
$1.6B68,944,100 shFMR LLC
$1.2B50,925,366 shBlackRock, Inc.
$1.1B47,622,630 shPRIMECAP MANAGEMENT CO/CA/
$1.1B45,840,956 shDIMENSIONAL FUND ADVISORS LP
$586.9M24,527,135 shVANGUARD PORTFOLIO MANAGEMENT LLC
$541.7M22,637,357 shVANGUARD CAPITAL MANAGEMENT LLC
$534.5M22,336,124 shSTATE STREET CORP
$367.0M15,336,479 shWinslow Capital Management, LLC
$325.8M13,614,355 shGEODE CAPITAL MANAGEMENT, LLC
$267.9M11,192,404 sh
| Fund | Value | Shares |
|---|---|---|
| DODGE & COX | $1.6B | 68,944,100 |
| FMR LLC | $1.2B | 50,925,366 |
| BlackRock, Inc. | $1.1B | 47,622,630 |
| PRIMECAP MANAGEMENT CO/CA/ | $1.1B | 45,840,956 |
| DIMENSIONAL FUND ADVISORS LP | $586.9M | 24,527,135 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $541.7M | 22,637,357 |
| VANGUARD CAPITAL MANAGEMENT LLC | $534.5M | 22,336,124 |
| STATE STREET CORP | $367.0M | 15,336,479 |
| Winslow Capital Management, LLC | $325.8M | 13,614,355 |
| GEODE CAPITAL MANAGEMENT, LLC | $267.9M | 11,192,404 |
More Healthcare Companies
View all Healthcare →Put ELAN on your watchlist
Track score changes the day Elanco Animal Health Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ELAN a good stock to buy?
13F Pro's AI-powered analysis of Elanco Animal Health Inc (ELAN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELAN are available on the ELAN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ELAN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELAN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Elanco Animal Health Inc's investment landscape.